NCT03945903 is a clinical trial of Golimumab in Diabetes Mellitus, Type 1, sponsored by Janssen Research & Development, LLC.

Who is sponsoring NCT03945903?

NCT03945903 is sponsored by Janssen Research & Development, LLC.

What drugs are being tested in NCT03945903?

Interventions in NCT03945903: Golimumab.

What condition does NCT03945903 study?

NCT03945903 studies Diabetes Mellitus, Type 1.

Is NCT03945903 still recruiting?

NCT03945903 is currently no longer available. Last updated 13 April 2023.

Last reviewed 2023-04-13 · How we verify

NCT03945903

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pre-Approval Access to Golimumab Subcutaneous for the Treatment of Stage 3 Type-1 Diabetes Mellitus in Children and Young Adults

NO LONGER AVAILABLE Last updated 13 April 2023

What this trial tests

trial testing Golimumab in Diabetes Mellitus, Type 1. No longer available.

Quick facts

Lead sponsor	Janssen Research & Development, LLC
Status	NO LONGER AVAILABLE
Study type	EXPANDED_ACCESS
Sites	1 location across United States

Drugs / interventions tested

Golimumab (GOLIMUMAB) — full drug profile →

Conditions studied

Diabetes Mellitus, Type 1 — all drugs for Diabetes Mellitus, Type 1 →

Sponsor

Janssen Research & Development, LLC — full company profile →

Who can join

Eligibility, any sex, with Diabetes Mellitus, Type 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Single Patient Investigational New Drug (IND) to golimumab subcutaneous (SC) for the treatment of recently diagnosed Stage 3 type-1 diabetes mellitus (T1D) in children and young adults. The main purpose of a single patient IND is to provide treatment to participants with serious/life-threatening diseases or conditions prior to marketing authorization.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Two-Year Follow-up From the T1GER Study: Continued Off-Therapy Metabolic Improvements in Children and Young Adults With New-Onset T1D Treated With Golimumab and Characterization of Responders.
Rigby MR, Hayes B, Li Y, Vercruysse F, et al · · 2023 · cited 41× · PMID 36576974 · DOI 10.2337/dc22-0908

Verify or expand the search:

Other trials of Golimumab

Trials testing the same drug.

NCT05960578 — Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study · Phase 2 · active not recruiting
NCT05242484 — A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati · Phase 2 · active not recruiting
NCT05242471 — A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's · Phase 2 · active not recruiting
NCT05164198 — REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST) · Phase 4 · unknown
NCT05071664 — A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis · Phase 2 · completed

Other recruiting trials for Diabetes Mellitus, Type 1

Currently open trials in the same condition.

NCT07325461 — Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes · NA · recruiting
NCT07305805 — A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes · Phase 1 · recruiting
NCT06282055 — Trajectories in Insulin Sensitivity Across MEnstrual cycleS in Women With Type 1 Diabetes · recruiting
NCT06325202 — Closed Loop and Education for Hypoglycemia Awareness Restoration · NA · recruiting
NCT07160816 — A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar · recruiting

Other Janssen Research & Development, LLC trials

Trials by the same sponsor.

NCT07518186 — A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 3 · not yet recruiting
NCT07309445 — A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC · recruiting
NCT07499232 — A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease · Phase 3 · not yet recruiting
NCT07438496 — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus · Phase 3 · recruiting
NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03945903 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Research & Development, LLC
Last refreshed: 13 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03945903.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing